Loading...
•
Sep 30, 2024
Jazz Pharmaceuticals Q3 2024 Earnings Report
Jazz Pharmaceuticals delivered record revenues and a year-over-year revenue increase from key growth drivers.
Key Takeaways
Jazz Pharmaceuticals announced strong Q3 2024 results with record revenues exceeding $1.05 billion. Key growth drivers, including Xywav, Epidiolex, and Rylaze, saw a combined 14% year-over-year revenue increase. The company has affirmed its 2024 total revenue guidance between $4.0 to $4.1 billion.
Key growth drivers grew 14% combined year-over-year.
Zepzelca and atezolizumab combination showed statistically significant and clinically meaningful improvement in OS and PFS primary endpoints.
Zanidatamab has a PDUFA date of November 29, with a 2L BTC commercial launch expected in 4Q24, following approval.
2024 total revenue guidance affirmed at $4.0 to $4.1 billion.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Jazz Pharmaceuticals Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
The company is updating its full year 2024 financial guidance and affirming 2024 total revenue guidance of $4.0 to $4.1 billion.
Positive Outlook
- Affirming 2024 total revenue guidance of $4.0 to $4.1 billion.
- Affirming neuroscience revenue guidance of $2.825 to $2.925 billion.
- Raising GAAP EPS guidance range to $6.70 to $8.50.
- Raising non-GAAP EPS guidance range to $19.50 to $20.60.
Challenges Ahead
- Lowering oncology revenue guidance to $1.08 to $1.13 billion.
- Lowering GAAP R&D expense guidance to $862 to $908 million.
- Lowering non-GAAP R&D expense guidance to $790 to $830 million.
- GAAP effective tax rate is expected to be between (17)% and (2)%.
- Non-GAAP adjusted effective tax rate is expected to be between 10% and 12%.